EM and VG have no conflicts of interest to disclose. SS is a consultant for Pfizer. KM contributed to this work while in the former role at Emory University and is now an employee of Pfizer. NJ receives research funding from Jannsen, Bristol-Myers Squibb, Novartis and Regeneron, and she is a consultant for Jannsen and Bristol-Myers Squibb. CH receives research funding from Sanofi, Bristol-Myers Squibb, Pfizer, Celgene and Cellularity, serves on the advisory board for Janssen and Abbvie, and is a consultant for Celgene, Imbrium, Janssen, Karyopharm, Nektar, Oncopeptides, and Sanofi Pasteur. MD serves as a consultant for Amgen, Celgene, Janssen, Kite Pharma, lava therapeutics, and Roche/Genentech. JK receives research funding from Abbvie/Genentech, Amgen, Bristol-Myers Squibb, Gelgene, Fortis Therapeutics, Janssen, Merck, and Sutro Biopharm, Inc and is a consultant for Bristol-Myers Squibb, Sanofi, Abbvie, and Incyte. SL receives research funding from Bristol-Myers Squibb, Celgene, and Takeda, and he is a Consultant for Abbvie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Juno Therapeutics, Merck, Novartis, and Takeda. AN receives research funding from Amgen, Janssen, and Takeda, and he is a Consultant for Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Oncopeptides, Sanofi Pharmaceuticals, and Takeda.